It is commonly used to support energy metabolism and cognitive function
Frequently Asked Questions Retatrutide sits in a research-only supply category in the UK as of 2026 because it holds no MHRA marketing authorisation and remains in Phase 3 clinical trials [5][6]
12.23) points) scores ( Supplementary table S5 )
SUSTAIN-6 compared semaglutide and placebo in 3,297 people with type 2 diabetes and established cardiovascular disease, chronic kidney disease, or both, or who were aged over 60 years and had subclinical evidence of cardiovascular disease (persistent microalbuminuria or proteinuria, hypertension with left ventricular hypertrophy, left ventricular dysfunction by imaging, ankle/brachial index less than 0.9)
First, we did not look at effectiveness of these drugs the values reported here were found prior to initiation of the prescriptions, and thus, cannot be used to infer drug effectiveness over time